Рецепт. 2020; : 828-837
Опыт применения этанерцептау детей с полиартикулярным вариантом ювенильного идиопатического артрита
https://doi.org/10.34883/PI.2020.23.6.003Аннотация
В статье представлен клинический опыт использования биологической терапии лекарственным средством этанерцепт у детей. В исследовании, проведенном с участием 30 детей с полиартикулярной формой ювенильного идиопатического артрита, показано, что этанерцепт быстро и эффективно снижает воспалительную активность заболевания, повышает функциональную активность пациентов, обладает хорошей переносимостью.
Список литературы
1. Belyaeva L., Chizhevskaya I. (2015) Bolezni sustavov u detej [Joint diseases in children]. Minsk: BelMAPO. (in Russian)
2. Geppe N., Podchernyaeva N., Lyskina G. (2011) Rukovodstvo po detskoj revmatologii [Guidelines on Children’s Rheumatology]. Moscow: GOE’TAR-Media. (in Russian)
3. Chizhevskaya I., Belyaeva L., Kozharskaja L. (2015) Vozmozhnosti ispol’zovanija biologicheskoj terapii u detej s juvenil’nym revmatoidnym artritom [Possibilities of using biological therapy in children with juvenile rheumatoid arthritis]. Medicinskaja panorama, no 8, рр. 22–27.
4. Wilkinson N., Jackson G., Gardner-Medwin J. (2003) Biologic therapies for juvenile arthritis. Arch Dis Child, no 88, pp. 186–191.
5. Carrasco R., Smith J.A., Lovell D. (2004) Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Pediatric Drugs, no 6, pp. 137–146.
6. Mihel’s H., Nikishina I.P., Fedorov E.S., Salugina S.O. (2011) Genno-inzhenernaya biologicheskaya terapiya yuvenil’nogo artrita [Genetically engineered biological treatment of juvenile arthritis]. Nauchno-prakticheskaya revmatologiya, no 1, pp. 78–93.
7. Beutler B.A. (1999) The role of tumor necrosis factor in health and disease. J Rheumatol Suppl, no 57, pp. 16–21.
8. McDevitt H., Munson S., Ettinger R., Wu A. (2002) Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity.Arthritis Res, no 4, рр. 141–152.
9. Sfikakis P.P., Kollias G. (2003) Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol, no 15, рр. 380–386.
10. Heiligenhaus A., Horneff G., Greiner K. (2007) Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheikd, vol. 224, no 6, pp. 526–531.
11. Beukelman T., Patkar N.M., Saag K.G., Tolleson-Rinehart S., Cron R.Q., DeWitt E.M. (2011) American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken), no 63, pp. 465–82.
12. Foeldvari I., Nielsen S., Kummerle-Deschner J., Espada G., Horneff G., Bica B. (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol, no 34, рр. 1146–1150.
13. Horneff G., De Bock F., Foeldvari I., Girschick H.J., Michels H., Moebius D. (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis, no 68, рр. 519–525.
14. Kietz D.A., Pepmueller P.H., Moore T.L. (2001) Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J. Rheumatol, no 28, рр. 360–362.
15. Lovell D.J., Giannini E.H., Reiff A., Jones O.Y., Schneider R., Olson J.C. (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum, no 48, рр. 218–226.
16. Lovell D.J., Reiff A., Jones O.Y., Schneider R. (2006) Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum, no 54, рр. 1987–1994.
17. Lovell D.J., Reiff A., Ilowite N.T., Wallace C.A. (2008) Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis. Arthritis Rheum, no 58, рр. 1496–1504.
18. Otten M., Prince F., Twilt M. (2010) Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J. Rheumatol, no 37, рр. 665–667.
19. Tynjala P., Lindahl P., Honkanen V., Lahdenne P., Kotaniemi K. (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis, no 66, рр. 548–550.
20. Pain C., McCann L. (2009) Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics: Targets & Therapy, no 3, рр. 127–139.
21. Petty R.E., Southwood T.R., Manners P. (2001) International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol, no 31, рр. 390–392.
Recipe. 2020; : 828-837
Experience of Use of Etanercept in Childrenwith a Polyarticular Variant of Juvenile Idiopathic Arthritis
https://doi.org/10.34883/PI.2020.23.6.003Abstract
References
1. Belyaeva L., Chizhevskaya I. (2015) Bolezni sustavov u detej [Joint diseases in children]. Minsk: BelMAPO. (in Russian)
2. Geppe N., Podchernyaeva N., Lyskina G. (2011) Rukovodstvo po detskoj revmatologii [Guidelines on Children’s Rheumatology]. Moscow: GOE’TAR-Media. (in Russian)
3. Chizhevskaya I., Belyaeva L., Kozharskaja L. (2015) Vozmozhnosti ispol’zovanija biologicheskoj terapii u detej s juvenil’nym revmatoidnym artritom [Possibilities of using biological therapy in children with juvenile rheumatoid arthritis]. Medicinskaja panorama, no 8, rr. 22–27.
4. Wilkinson N., Jackson G., Gardner-Medwin J. (2003) Biologic therapies for juvenile arthritis. Arch Dis Child, no 88, pp. 186–191.
5. Carrasco R., Smith J.A., Lovell D. (2004) Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Pediatric Drugs, no 6, pp. 137–146.
6. Mihel’s H., Nikishina I.P., Fedorov E.S., Salugina S.O. (2011) Genno-inzhenernaya biologicheskaya terapiya yuvenil’nogo artrita [Genetically engineered biological treatment of juvenile arthritis]. Nauchno-prakticheskaya revmatologiya, no 1, pp. 78–93.
7. Beutler B.A. (1999) The role of tumor necrosis factor in health and disease. J Rheumatol Suppl, no 57, pp. 16–21.
8. McDevitt H., Munson S., Ettinger R., Wu A. (2002) Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity.Arthritis Res, no 4, rr. 141–152.
9. Sfikakis P.P., Kollias G. (2003) Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol, no 15, rr. 380–386.
10. Heiligenhaus A., Horneff G., Greiner K. (2007) Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin. Monatsbl. Augenheikd, vol. 224, no 6, pp. 526–531.
11. Beukelman T., Patkar N.M., Saag K.G., Tolleson-Rinehart S., Cron R.Q., DeWitt E.M. (2011) American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken), no 63, pp. 465–82.
12. Foeldvari I., Nielsen S., Kummerle-Deschner J., Espada G., Horneff G., Bica B. (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol, no 34, rr. 1146–1150.
13. Horneff G., De Bock F., Foeldvari I., Girschick H.J., Michels H., Moebius D. (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis, no 68, rr. 519–525.
14. Kietz D.A., Pepmueller P.H., Moore T.L. (2001) Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J. Rheumatol, no 28, rr. 360–362.
15. Lovell D.J., Giannini E.H., Reiff A., Jones O.Y., Schneider R., Olson J.C. (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum, no 48, rr. 218–226.
16. Lovell D.J., Reiff A., Jones O.Y., Schneider R. (2006) Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum, no 54, rr. 1987–1994.
17. Lovell D.J., Reiff A., Ilowite N.T., Wallace C.A. (2008) Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis. Arthritis Rheum, no 58, rr. 1496–1504.
18. Otten M., Prince F., Twilt M. (2010) Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept. J. Rheumatol, no 37, rr. 665–667.
19. Tynjala P., Lindahl P., Honkanen V., Lahdenne P., Kotaniemi K. (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis, no 66, rr. 548–550.
20. Pain C., McCann L. (2009) Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics: Targets & Therapy, no 3, rr. 127–139.
21. Petty R.E., Southwood T.R., Manners P. (2001) International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol, no 31, rr. 390–392.
